Fused thiazole derivatives as kinase inhibitors
View Patent ↗A series of 6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-4(5H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
1. A compound of formula (I), or a pharmaceutically acceptable salt thereof:
wherein
X represents oxygen or sulphur;
Y represents a group of formula CR 6 R 7 or NR 8 ;
R 1 represents hydrogen or C 1-6 alkyl; and
R 2 represents hydrogen; or C 1-6 alkyl, C 1-6 alkoxy, C 3-7 cycloalkyl, C 3-7 cycloalkyl(C 1-6 )alkyl, aryl, aryl(C 1-6 )alkyl, C 3-7 heterocycloalkyl, C 3-7 heterocycloalkyl(C 1-6 )alkyl, heteroaryl or heteroaryl(C 1-6 )alkyl, any of which groups may be optionally substituted by one or more substituents; or
R 1 and R 2 , when taken together with the carbon atom to which they are both attached, represent C 3-7 cycloalkyl or C 3-7 heterocycloalkyl, either of which groups may be optionally substituted by one or more substituents;
R 3 and R 4 independently represent hydrogen; or C 1-6 alkyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl(C 1-6 )alkyl, aryl, aryl(C 1-6 )alkyl, aryl(C 2-6 )alkenyl, aryl(C 2-6 )-alkynyl, biaryl(C 1-6 )alkyl, C 3-7 heterocycloalkyl, C 3-7 heterocycloalkyl(C 1-6 )alkyl, C 3-7 heterocycloalkylcarbonyl, heteroaryl, heteroaryl(C 1-6 )alkyl, heteroaryl-aryl(C 1-6 )alkyl or arylheteroaryl(C 1-6 )alkyl, any of which groups may be optionally substituted by one or more substituents; or
R 3 and R 4 , when both are attached to the same carbon atom, represent, when taken together with the carbon atom to which they are both attached, C 3-7 cycloalkyl or C 3-7 heterocycloalkyl, either of which groups may be optionally substituted by one or more substituents; or
R 3 and R 4 , when attached to adjacent carbon atoms, represent, when taken together with the carbon atoms to which they are attached, C 5-7 cycloalkyl, phenyl or heteroaryl, any of which groups may be optionally benzo-fused and/or substituted by one or more substituents;
R 5 represents hydrogen or C 1-6 alkyl;
R 6 represents hydrogen; or C 1-6 alkyl, C 1-6 alkoxy, C 3-7 cycloalkyl, C 3-7 cycloalkyl(C 1-6 )alkyl, aryl, aryl(C 1-6 )alkyl, C 3-7 heterocycloalkyl, C 3-7 heterocycloalkyl(C 1-6 )alkyl, heteroaryl or heteroaryl(C 1-6 )alkyl, any of which groups may be optionally substituted by one or more substituents; and
R 7 represents hydrogen or C 1-6 alkyl; or
R 6 and R 7 , when taken together with the carbon atom to which they are both attached, represent C 3-7 cycloalkyl or C 3-7 heterocycloalkyl, either of which groups may be optionally substituted by one or more substituents; or
R 2 and R 6 , when taken together with the carbon atoms to which they are attached, represent C 5-7 cycloalkyl, phenyl or heteroaryl, any of which groups may be optionally benzo-fused and/or substituted by one or more substituents; and
R 8 represents hydrogen; or C 1-6 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl(C 1-6 )alkyl, aryl, aryl(C 1-6 )alkyl, C 3-7 heterocycloalkyl, C 3-7 heterocycloalkyl-(C 1-6 )alkyl, heteroaryl or heteroaryl(C 1-6 )alkyl, any of which groups may be optionally substituted by one or more substituents; or
R 2 and R 8 , when taken together with the carbon and nitrogen atoms to which they are respectively attached, represent C 5-7 heterocycloalkyl or heteroaryl, either of which groups may be optionally benzo-fused and/or substituted by one or more substituents.
2. A compound as claimed in claim 1 represented by formula (IIA), or a pharmaceutically acceptable salt thereof:
wherein
R 11 represents hydrogen or C 1-6 alkyl; and
R 12 represents hydrogen; or C 1-6 alkyl, C 1-6 alkoxy, C 3-7 cycloalkyl, C 3-7 cycloalkyl(C 1-6 )alkyl, aryl, aryl(C 1-6 )alkyl, C 3-7 heterocycloalkyl, C 3-7 heterocycloalkyl(C 1-6 )alkyl, heteroaryl or heteroaryl(C 1-6 )alkyl, any of which groups may be optionally substituted by one or more substituents; or
R 11 and R 12 , when taken together with the carbon atom to which they are both attached, represent C 3-7 cycloalkyl or C 3-7 heterocycloalkyl, either of which groups may be optionally substituted by one or more substituents; and
R 13 represents hydrogen; or C 1-6 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl(C 1-6 )alkyl, aryl, aryl(C 1-6 )alkyl, aryl(C 2-6 )alkenyl, aryl(C 2-6 )alkynyl, biaryl(C 1-6 )alkyl, C 3-7 heterocycloalkyl, C 3-7 heterocycloalkyl(C 1-6 )alkyl, C 3-7 heterocycloalkylcarbonyl, heteroaryl, heteroaryl(C 1-6 )alkyl, heteroaryl-aryl(C 1-6 )alkyl or aryl-heteroaryl(C 1-6 )alkyl, any of which groups may be optionally substituted by one or more substituents.
3. A compound as claimed in claim 2 represented by formula (IIB), or a pharmaceutically acceptable salt thereof:
wherein
R 11 represents hydrogen or C 1-6 alkyl; and
R 12 represents hydrogen; or C 1-6 alkyl, C 1-6 alkoxy, C 3-7 cycloalkyl, C 3-7 cycloalkyl(C 1-6 )alkyl, aryl, aryl(C 1-6 )alkyl, C 3-7 heterocycloalkyl, C 3-7 heterocycloalkyl(C 1-6 )alkyl, heteroaryl or heteroaryl(C 1-6 )alkyl, any of which groups may be optionally substituted by one or more substituents; or
R 11 and R 12 , when taken together with the carbon atom to which they are both attached, represent C 3-7 cycloalkyl or C 3-7 heterocycloalkyl, either of which groups may be optionally substituted by one or more substituents; and
T represents N—R 25 ;
V represents carbon or nitrogen;
W represents carbon or nitrogen;
R 23 represents hydrogen, halogen, cyano, nitro, C 1-6 alkyl, hydroxy(C 1-6 )alkyl, trifluoromethyl, aryl(C 1-6 )alkyl, oxazolinyl, triazolyl, hydroxy, C 1-6 alkoxy, difluoromethoxy, trifluoromethoxy, C 3-7 cycloalkoxy, C 3-7 cycloalkyl(C 1-6 )alkoxy, morpholinyl(C 1-6 )alkoxy, aryloxy, aryl(C 1-6 )alkoxy, C 1-6 alkylthio, C 1-6 alkylsulphinyl, arylsulphinyl, arylsulphonyl, C 1-6 alkylsulphonyloxy, amino, azetidinyl, morpholinyl, C 2-6 alkylcarbonylamino, C 2-6 alkylcarbonylaminomethyl, C 2-6 alkoxycarbonylamino, [(C 2-6 )alkoxycarbonyl][(C 1-6 )alkyl]amino, C 1-6 alkylsulphonylamino, C 2-6 alkylcarbonyl, C 2-6 alkylcarbonyl oxime, C 2-6 alkylcarbonyl O-(methyl)oxime, trifluoromethylcarbonyl, carboxy, C 2-6 alkoxycarbonyl, aminocarbonyl, C 1-6 alkylaminocarbonyl, [hydroxy(C 1-6 )alkyl]aminocarbonyl, [di(C 1-6 )alkylamino(C 1-6 )alkyl]aminocarbonyl, di(C 1-6 )alkylaminocarbonyl, [(C 1-6 )alkyl][cyano(C 1-6 )alkyl]aminocarbonyl, [(C 1-6 )alkyl][hydroxy(C 1-6 )alkyl]aminocarbonyl, [(C 1-6 )alkoxy(C 1-6 )alkyl][(C 1-6 )alkyl]aminocarbonyl, [di(C 1-6 )alkylamino(C 1-6 )alkyl][(C 1-6 )alkyl]aminocarbonyl, C 3-7 cycloalkyl(C 1-6 )alkylaminocarbonyl, aryl(C 1-6 )alkylaminocarbonyl, heteroarylaminocarbonyl, heteroaryl(C 1-6 )alkylamino-carbonyl, azetidinylcarbonyl, hydroxyazetidinylcarbonyl, aminoazetidinylcarbonyl, C 2-6 alkoxycarbonylaminoazetidinylcarbonyl, pyrrolidinylcarbonyl, (C 1-6 )alkylpyrrolidinylcarbonyl, C 1-6 alkoxy(C 1-6 )alkylpyrrolidinylcarbonyl, di(C 1-6 )alkylaminopyrrolidinyl-carbonyl, thiazolidinylcarbonyl, oxothiazolidinylcarbonyl, piperidinylcarbonyl, (C 1-6 )alkylpiperazinylcarbonyl, morpholinylcarbonyl, C 1-6 alkylsulphonyl, C 1-6 alkylsulphonylmethyl or di(C 1-6 )alkylaminosulphonyl; and
R 24 represents hydrogen, halogen, C 1-6 alkoxy or di(C 1-6 )alkylaminocarbonyl; or
R 23 and R 24 , when situated on adjacent carbon atoms, together represent methylenedioxy or difluoromethylenedioxy; and
R 25 represents hydrogen.
4. A compound as claimed in claim 2 represented by formula (IIC), or a pharmaceutically acceptable salt thereof:
wherein
R 11 represents hydrogen or C 1-6 alkyl; and
R 12 represents hydrogen; or C 1-6 alkyl, C 1-6 alkoxy, C 3-7 cycloalkyl, C 3-7 cycloalkyl(C 1-6 )alkyl, aryl, aryl(C 1-6 )alkyl, C 3-7 heterocycloalkyl, C 3-7 heterocycloalkyl-(C 1-6 )alkyl, heteroaryl or heteroaryl(C 1-6 )alkyl, any of which groups may be optionally substituted by one or more substituents; or
R 11 and R 12 , when taken together with the carbon atom to which they are both attached, represent C 3-7 cycloalkyl or C 3-7 heterocycloalkyl, either of which groups may be optionally substituted by one or more substituents; and
R 33 represents halogen or —NHR 34 ; or aryl or heteroaryl, either of which groups may be optionally substituted by one or more substituents; and
R 34 represents methylenedioxyphenyl, morpholinyl(C 1-6 )alkylphenyl, oxazolinylphenyl, [(C 1-6 )alkyl](oxo)pyrazolylphenyl, oxazolylphenyl, isoxazolylphenyl, triazolyl-phenyl, (C 1-6 )alkyltriazolylphenyl, (C 1-6 )alkylpyrimidinylphenyl, pyrazolyl(C 1-6 )alkyl-phenyl, triazolyl(C 1-6 )alkylphenyl, C 1-6 alkylsulphonylaminophenyl, morpholinylcarbonyl-phenyl, C 1-6 alkylsulphonylphenyl, morpholinylsulphonylphenyl, dihydrobenzofuranyl, C 1-6 alkylsulphonylindolinyl, chromanonyl, dihydroquinolinonyl, benzoxazinonyl, benzothienyl, indolyl, dioxoindolyl, [(C 1-6 )alkyl](halo)pyrazolyl, tri(C 1-6 )alkylpyrazolyl, (C 1-6 )alkylindazolyl, benzoxazolyl, benzoxazolonyl, di(C 1-6 )alkylisoxazolyl, benzothiazolyl, (C 1-6 )alkylisothiazolyl, (C 1-6 )alkylbenzimidazolyl, benzimidazolonyl, di(C 1-6 )alkylbenzimidazolonyl, (C 1-6 )alkyloxadiazolyl, furyloxadiazolyl, pyridinyl, halopyridinyl, (C 1-6 )alkylpyridinyl, di(C 1-6 )alkylpyridinyl, (C 1-6 )alkoxypyridinyl, oxopyridinyl, oxopyrimidinyl, thioxopyrimidinyl, [(C 1-6 )alkoxy](halo)pyridazinyl, (C 1-6 )alkylcinnolinyl, quinoxalinyl or (C 1-6 )alkylchromenyl.
5. A compound as claimed in claim 1 represented by formula (IID-1) or (IID-2), or a pharmaceutically acceptable salt thereof:
wherein
R 11 represents hydrogen or C 1-6 alkyl; and
R 12 represents hydrogen; or C 1-6 alkyl, C 1-6 alkoxy, C 3-7 cycloalkyl, C 3-7 cycloalkyl(C 1-6 )alkyl, aryl, aryl(C 1-6 )alkyl, C 3-7 heterocycloalkyl, C 3-7 heterocycloalkyl(C 1-6 )alkyl, heteroaryl or heteroaryl(C 1-6 )alkyl, any of which groups may be optionally substituted by one or more substituents; or
R 11 and R 12 , when taken together with the carbon atom to which they are both attached, represent C 3-7 cycloalkyl or C 3-7 heterocycloalkyl, either of which groups may be optionally substituted by one or more substituents; and
R 43 represents hydrogen, halogen, nitro, C 1-6 alkyl, C 2-6 alkenyl, C 3-7 cycloalkyl, (C 1-6 )alkylaryl, di(C 1-6 )alkylaryl, piperidinyl(C 1-6 )alkylaryl, piperazinyl(C 1-6 )alkylaryl, (C 1-6 )alkylpiperazinyl(C 1-6 )alkylaryl, morpholinyl(C 1-6 )alkylaryl, (C 1-6 )alkoxyaryl, cyano(C 1-6 )alkoxyaryl, di(C 1-6 )alkylamino(C 1-6 )alkylaryl, (C 1-6 )alkylaminocarbonylaryl, aryl(C 1-6 )alkyl, haloarylpyrrolidinyl, dioxopyrrolidinyl, aminopyrrolidinyl, di(C 1-6 )alkylaminopyrrolidinyl, indolinyl, oxoindolinyl, arylpiperidinyl, arylcarbonylpiperidinyl, di(C 1-6 )alkylaminocarbonylpiperidinyl, piperazinyl, (C 1-6 )alkylpiperazinyl, haloaryl-piperazinyl, pyridinylpiperazinyl, furoylpiperazinyl, homopiperazinyl, (C 1-6 )alkyl-homopiperazinyl, (C 1-6 )alkylpiperazinyl(C 1-6 )alkyl, morpholinyl(C 1-6 )alkyl, benzofuryl, benzothienyl, pyrazolyl, (C 1-6 )alkylpyrazolyl, di(C 1-6 )alkylpyrazolyl, tri(C 1-6 )alkyl-pyrazolyl, [di(C 1-6 )alkyl](trifluoromethyl)pyrazolyl, cyano(C 1-6 )alkylpyrazolyl, [cyano(C 1-6 )alkyl][di(C 1-6 )alkyl]pyrazolyl, hydroxy(C 1-6 )alkylpyrazolyl, [hydroxy(C 1-6 )alkyl][di(C 1-6 )alkyl]pyrazolyl, methoxy(C 1-6 )alkylpyrazolyl, [(hydroxy)(methoxy)(C 1-6 )alkyl]pyrazolyl, amino(C 1-6 )alkylpyrazolyl, [(C 1-6 )alkyl][amino(C 1-6 )alkyl]pyrazolyl, [amino(C 1-6 )alkyl][di(C 1-6 )alkyl]pyrazolyl, di(C 1-6 )alkylamino(C 1-6 )alkylpyrazolyl, di(C 1-6 )alkoxyphosphono(C 1-6 )alkylpyrazolyl, (C 2-6 )alkenylpyrazolyl, (C 3-7 )cycloalkyl(C 1-6 )alkylpyrazolyl, [(C 3-7 )cycloalkyl(C 1-6 )alkyl][di(C 1-6 )alkyl]pyrazolyl, [(C 1-6 )alkyl]-(aryl)pyrazolyl, (aryl)(trifluoromethyl)pyrazolyl, aryl(C 1-6 )alkylpyrazolyl, aminoaryl(C 1-6 )alkylpyrazolyl, piperidinylpyrazolyl, tetrahydropyranyl(C 1-6 )alkylpyrazolyl, [di(C 1-6 )alkyl][tetrahydropyranyl(C 1-6 )alkyl]pyrazolyl, pyrrolidinyl(C 1-6 )alkylpyrazolyl, piperidinyl(C 1-6 )alkylpyrazolyl, (C 1-6 )alkylpiperidinyl(C 1-6 )alkylpyrazolyl, morpholinyl(C 1-6 )alkylpyrazolyl, pyridinyl(C 1-6 )alkylpyrazolyl, oxypyridinyl(C 1-6 )alkylpyrazolyl, [arylcarbonyl(C 1-6 )alkyl][di(C 1-6 )alkyl]pyrazolyl, [(C 1-6 )alkyl](piperazinylcarbonyl)pyrazolyl, [(C 1-6 )alkylaminocarbonyl][(C 1-6 )alkylaryl]pyrazolyl, [(C 1-6 )alkyl]-[amino(C 1-6 )alkylaminocarbonyl]pyrazolyl, aminocarbonyl(C 1-6 )alkylpyrazolyl, [aminocarbonyl(C 1-6 )alkyl][di(C 1-6 )alkyl]pyrazolyl, di(C 1-6 )alkylaminocarbonyl(C 1-6 )alkylpyrazolyl, pyrazolo[1,5-c]pyridinyl, di(C 1-6 )alkylisoxazolyl, (amino)[(C 1-6 )alkyl]-isoxazolyl, thiazolyl, di(C 1-6 )alkylthiazolyl, imidazolyl, (C 1-6 )alkylimidazolyl, di(C 1-6 )-alkylimidazolyl, imidazo[1,2-c]pyridinyl, (C 1-6 )alkylimidazo[1,2-c]pyridinyl, (C 1-6 )-alkylimidazo[4,5-b]pyridinyl, imidazo[1,2-c]pyrimidinyl, imidazo[1,2-c]pyrazinyl, (C 1-6 )-alkylthiadiazolyl, pyridinyl, halopyridinyl, (C 1-6 )alkyl-pyridinyl, [(C 1-6 )alkyl](halo)-pyridinyl, di(C 1-6 )alkylpyridinyl, (C 2-6 )alkenylpyridinyl, (C 1-6 )alkylpiperazinylpyridinyl, [(C 1-6 )alkyl](piperazinyl)pyridinyl, [(C 1-6 )alkoxycarbonylpiperazinyl][(C 1-6 )alkyl]-pyridinyl, piperidinyl(C 1-6 )alkylpyridinyl, [(C 1-6 )alkyl](oxy)pyridinyl, hydroxypyridinyl, hydroxy(C 1-6 )alkylpyridinyl, (C 1-6 )alkoxypyridinyl, [(C 1-6 )alkoxy][(C 1-6 )alkyl]pyridinyl, [(C 1-6 )alkoxy][di(C 1-6 )alkyl]pyridinyl, (C 1-6 )alkoxy(C 1-6 )alkylpyridinyl, aminopyridinyl, carboxy(C 1-6 )alkylpyridinyl, (C 1-6 )alkoxycarbonyl(C 1-6 )alkylpyridinyl, pyridazinyl, (C 1-6 )alkylpyridazinyl, piperidinylpyridazinyl, oxypyridazinyl, (C 1-6 )alkoxypyridazinyl, aminopyridazinyl, hydroxy(C 1-6 )alkylaminopyridazinyl, di(C 1-6 )alkylaminopyridazinyl, pyrimidinyl, (C 1-6 )alkylpyrimidinyl, [(C 1-6 )alkyl](halo)pyrimidinyl, di(C 1-6 )alkyl-pyrimidinyl, pyrrolidinylpyrimidinyl, (C 1-6 )alkylpiperazinylpyrimidinyl, [(C 1-6 )alkyl](piperazinyl)pyrimidinyl, [(C 1-6 )alkoxycarbonyl][(C 1-6 )alkyl]piperazinylpyrimidinyl, hydroxypyrimidinyl, [(C 1-6 )alkyl](hydroxy)pyrimidinyl, [(C 1-6 )alkyl]-[hydroxy(C 1-6 )alkyl]pyrimidinyl, [(C 1-6 )alkyl][hydroxy(C 2-6 )alkynyl]pyrimidinyl, (C 1-6 )alkoxypyrimidinyl, aminopyrimidinyl, di(C 1-6 )alkylaminopyrimidinyl, [di(C 1-6 )alkylamino](halo)pyrimidinyl, carboxypyrimidinyl, [(C 1-6 )alkoxycarbonyl(C 1-6 )alkyl][(C 1-6 )alkyl]pyrimidinyl, aminocarbonylpyrimidinyl, pyrazinyl, (C 1-6 )alkoxypyrazinyl, aminopyrazinyl, hydroxy, (C 1-6 )alkoxy, aryl(C 1-6 )alkoxycarbonylpiperidinyloxy, morpholinyl(C 1-6 )alkoxy, aryloxy, haloaryloxy, di(C 1-6 )alkylpyrazolyloxy, halopyridinyloxy, pyrrolidinylpyridinyloxy, (C 1-6 )alkylpiperazinylpyridinyloxy, (C 1-6 )alkylpyrazolylpyridinyloxy, (C 1-6 )alkylaminopyridinyloxy, carboxypyridinyloxy, aminocarbonylpyridinyloxy, (C 1-6 )alkylpyridazinyloxy, pyrimidinyloxy, (C 1-6 )alkylpyrimidinyloxy, [(C 1-6 )alkyl](halo)pyrimidinyloxy, hydroxy(C 1-6 )alkyl, dihydroxy(C 1-6 )alkyl, pyridinyloxy(C 1-6 )alkyl, amino, (C 1-6 )alkylamino, dihydroxy(C 1-6 )alkylamino, (C 1-6 )alkoxy(C 1-6 )alkylamino, N—[(C 1-6 )alkoxy(C 1-6 )alkyl]-N—[(C 1-6 )alkyl]amino, di(C 1-6 )alkylamino(C 1-6 )alkylamino, N—[(C 1-6 )alkyl]-N-[di(C 1-6 )alkylamino(C 1-6 )alkyl]amino, N—[(C 1-6 )alkyl]-N—[(C 3-7 )cycloalkyl]amino, haloarylamino, N—[(C 1-6 )alkyl]-N-(haloaryl)amino, N—[(C 1-6 )alkyl]-N—[aryl(C 1-6 )alkyl]amino, N-[di(C 1-6 )alkylamino(C 1-6 )alkyl]-N—[aryl(C 1-6 )alkyl]amino, cyanoaryl(C 1-6 )alkylamino, (cyano)(halo)aryl(C 1-6 )alkylamino, methylenedioxyaryl(C 1-6 )alkylamino, N—[(C 1-6 )alkyl]-N—[(C 1-6 )alkylpyrrolidinyl]amino, piperidinylamino, N—[(C 1-6 )alkyl]-N-(piperidinyl)amino, N—[(C 3-7 )cycloalkyl(C 1-6 )alkyl]-N(piperidinyl)amino, (C 1-6 )alkylpiperidinylamino, N—[(C 1-6 )alkyl]-N—[(C 1-6 )alkylpiperidinyl]amino, N—[(C 1-6 )alkyl]-N—[(C 3-7 )cycloalkylpiperidinyl]amino, N—[(C 1-6 )alkyl]-N—[(C 2-6 )alkylcarbonylpiperidinyl]amino, pyrrolidinyl(C 1-6 )alkylamino, N—[(C 1-6 )alkyl]-N—[pyrrolidinyl(C 1-6 )alkyl]amino, N—[(C 1-6 )alkyl]-N-[piperidinyl(C 1-6 )alkyl]amino, (C 1-6 )alkylpyrazolylamino, di(C 1-6 )alkylpyrazolylamino, tri(C 1-6 )alkylpyrazolylamino, N—[(C 1-6 )alkyl]-N—[(C 1-6 )alkylpyrazolyl]amino, thiazolylamino, imidazolylamino, [(C 1-6 )alkoxycarbonyl][(C 1-6 )alkyl]imidazolylamino, (C 1-6 )alkylthiadiazolylamino, pyridinylamino, halopyridinylamino, (C 1-6 )alkylpyridinylamino, di(C 1-6 )alkylpyridinylamino, trifluoromethylpyridinylamino, hydroxypyridinylamino, hydroxy(C 1-6 )alkylpyridinylamino, dihydroxy(C 1-6 )alkylpyridinylamino, (C 1-6 )alkoxypyridinylamino, dihydroxy(C 1-6 )alkoxypyridinylamino, di(C 1-6 )alkyldioxolanyl(C 1-6 )alkoxypyridinylamino, (C 1-6 )alkoxy(C 1-6 )alkylpyridinylamino, (C 1-6 )alkoxy(C 2-6 )alkenylpyridinylamino, dihydroxy(C 1-6 )alkylaminopyridinylamino, di(C 1-6 )alkylaminopyridinylamino, (C 1-6 )alkylamino(C 1-6 )alkylpyridinylamino, di(C 1-6 )alkylamino(C 1-6 )alkylpyridinylamino, carboxypyridinylamino, N—[(C 1-6 )alkyl]-N—[(C 1-6 )alkylpyridinyl]amino, bis[(C 1-6 )alkylpyridinyl]amino, bis(trifluoromethylpyridinyl)amino, isoquinolinylamino, (C 1-6 )alkylpyridazinylamino, N—[(C 1-6 )alkyl]-N—[(C 1-6 )alkylpyridazinyl]amino, N-[aryl(C 1-6 )alkyl]-N—[(C 1-6 )alkylpyridazinyl]amino, di(C 1-6 )alkylpyridazinylamino, arylpyridazinylamino, piperidinylpyridazinylamino, (C 1-6 )alkoxypyridazinylamino, di(C 1-6 )alkylaminopyridazinylamino, bis[(C 1-6 )alkylpyridazinyl]-amino, benzofuryl(C 1-6 )alkylamino, thienyl(C 1-6 )alkylamino, indolyl(C 1-6 )alkylamino, (C 1-6 )alkylpyrazolyl(C 1-6 )alkylamino, [di(C 1-6 )alkyl](halo)pyrazolyl(C 1-6 )alkylamino, di(C 1-6 )alkylisoxazolyl(C 1-6 )alkylamino, thiazolyl(C 1-6 )alkylamino, imidazolyl(C 1-6 )alkylamino, (C 1-6 )alkylimidazolyl(C 1-6 )alkylamino, pyridinyl(C 1-6 )alkylamino, (C 1-6 )alkylpyridinyl(C 1-6 )alkylamino, N—[(C 1-6 )alkyl]-N-[pyridinyl(C 1-6 )alkyl]amino, N-[dihydroxy(C 1-6 )alkyl]-N-[pyridinyl(C 1-6 )alkyl]amino, N—[(C 1-6 )alkylpyridinyl(C 1-6 )alkyl]-N-[dihydroxy(C 1-6 )alkyl]amino, amino(C 1-6 )alkyl, (C 1-6 )alkylamino(C 1-6 )alkyl, di(C 1-6 )alkylamino(C 1-6 )alkyl, pyridinylamino(C 1-6 )alkyl, N—[(C 2-6 )alkylcarbonyl]-N—[(C 1-6 )alkylpyridinyl(C 1-6 )alkyl]amino, di(C 1-6 )alkylamino(C 1-6 )alkylcarbonylamino, (C 3-7 )cycloalkylcarbonylamino, (C 1-6 )alkylpiperidinylcarbonylamino, (C 1-6 )alkylimidazolylcarbonylamino, formyl, C 2-6 alkylcarbonyl, (C 1-6 )alkylpiperidinylaminocarbonyl, N—[(C 1-6 )alkyl]-N—[(C 1-6 )alkylpiperidinyl]aminocarbonyl, piperidinyl(C 1-6 )alkylaminocarbonyl, (C 1-6 )alkylpiperazinylcarbonyl, C 1-6 alkylthio, C 1-6 alkylsulphinyl, C 1-6 alkylsulphonyl, C 2-6 alkoxycarbonyloxy or tetra(C 1-6 )alkyldioxaborolanyl; and
R 44 represents hydrogen, halogen, C 1-6 alkyl or C 1-6 alkoxy.
6. A compound as claimed in claim 1 represented by formula (IIE), or a pharmaceutically acceptable salt thereof:
wherein
R 13 represents hydrogen; or C 1-6 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl(C 1-6 )alkyl, aryl, aryl(C 1-6 )alkyl, aryl(C 2-6 )alkenyl, aryl(C 2-6 )alkynyl, biaryl(C 1-6 )alkyl, C 3-7 heterocycloalkyl, C 3-7 heterocycloalkyl(C 1-6 )alkyl, C 3-7 heterocycloalkylcarbonyl, heteroaryl, heteroaryl(C 1-6 )alkyl, heteroaryl-aryl(C 1-6 )alkyl or aryl-heteroaryl(C 1-6 )alkyl, any of which groups may be optionally substituted by one or more substituents.
7. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1 , or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.